-
Neighborhood Level Socioeconomic Disadvantage and Adherence to Guidelines for the Evaluation of Patients with Incidentally Detected Pulmonary Nodules. Chest (IF 9.5) Pub Date : 2024-12-16 Jacob M Abrahams,Beth Creekmur,Janet Shin Lee,In-Lu Amy Liu,Mayra Macias,Michael K Gould
BACKGROUND The management of incidental pulmonary nodules is guided by recommendations set forth by the Fleischner Society. While most pulmonary nodules are benign, timely and evidence-based follow-up can reduce morbidity and mortality. There are known socioeconomic disparities for engagement with recommended cancer screenings, however it is unclear whether disparities exist for follow-up of incidentally
-
How I Do It: Managing Cavitary Coccidioidomycosis Expert Opinions for Improving Patient Outcomes. Chest (IF 9.5) Pub Date : 2024-12-13 Fariba M Donovan,George R Thompson,Janis E Blair,Royce H Johnson,Josh Malo,Waseem Albasha,Stephanie G Worrell,Staci E Beamer,Kavitha Yaddanapudi,John N Galgiani,Neil M Ampel
Coccidioidomycosis (CM), caused by the dimorphic fungi Coccidioides immitis (C. immitis) and C. posadasii, is recognized as an increasing threat both nationally and worldwide. This is in large part secondary to the expanding range of Coccidioides spp. and increased international travel to endemic regions. The majority of individuals exposed to airborne Coccidioides organisms do not need medical attention
-
Performance of Lung Ultrasound as a Screening Tool for Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: a Multicenter Study. Chest (IF 9.5) Pub Date : 2024-12-13 Otaola Maria,Vasarmidi Eirini,Ottaviani Sébastien,Gutierrez Marwin,Dalpiaz Marina Soledad,Gaser Adrian,Juge Pierre-Antoine,Bertolazzi Chiara,Avgoustidis Nestor,Skiadas Christos,Della Maggiora Maricel,Orausclio Paola,Quintana-Rodriguez Alan,Debray Marie-Pierre,Perez Cepas Barbara,Schneeberger Emilce,Sidiropoulos Prodromos,Lloves Schenone Nicolas,Rosemffet Marcos,Marciano Sebastian,Antoniou Katerina
BACKGROUND The screening strategy for interstitial lung disease (ILD) in rheumatoid arthritis patients is currently debated. While high-resolution computed tomography (HRCT) is the gold standard for diagnosing ILD, its systematic use as a screening tool is not yet recommended. The role of lung ultrasound (LUS) in assessing ILD has been previously explored. RESEARCH QUESTION What is the performance
-
The effects of low-dose morphine on sleep and breathlessness in COPD: A randomized trial. Chest (IF 9.5) Pub Date : 2024-12-13 Thomas James Altree,Alison Pinczel,Barbara Toson,Kelly Loffler,Anna Hudson,Jim Zeng,Simon Proctor,Ganesh Naik,Sutapa Mukherjee,Peter Catcheside,Andrew Somogyi,David Currow,Danny Eckert
BACKGROUND Low-dose morphine may be prescribed to reduce chronic breathlessness in chronic obstructive pulmonary disease (COPD). Recent subjective findings suggest morphine may influence breathlessness through sleep-related mechanisms. However, concerns exist regarding opioid safety in COPD. The effects of morphine during sleep in COPD have not been objectively investigated. This study aimed to objectively
-
Missed Opportunities for Lung Cancer Screening among Behavioral Health Patients with Elevated Cigarette Smoking Rates: Lung Cancer Screening and Behavioral Health. Chest (IF 9.5) Pub Date : 2024-12-12 Anastasia Rogova,Lisa M Lowenstein,Lorraine R Reitzel,Kathleen Casey,Robert J Volk
Annual lung cancer screening using low dose computed tomography (LDCT) effectively reduces mortality from lung cancer and is recommended for persons who are at high risk of developing the disease. The utilization of the lung cancer screening, however, has remained low. Due to significantly higher cigarette smoking rates, patients with behavioral health disorders (those living with mental illness and/or
-
Promoting Prevention and Targeting Remission of Asthma A EUFOREA Consensus Statement on Raising the Bar in Asthma Care. Chest (IF 9.5) Pub Date : 2024-12-11 Milos Jesenak,Dr Anna Bobcakova,Ratko Djukanovic,Mina Gaga,Nicola A Hanania,Liam G Heaney,Ian Pavord,Santiago Quirce,Dr Dermot Ryan,Wytske Fokkens,Dr Diego Conti,Peter W Hellings,Glenis Scadding,Elizabeth Van Staeyen,Leif H Bjermer,Zuzana Diamant
TOPIC IMPORTANCE Asthma is a common multifaceted respiratory disease with a major impact on quality of life. Despite increased insights into mechanisms underlying various asthma phenotypes/endotypes and the availability of targeted biologic treatment options, a substantial proportion of patients remains uncontrolled with risk of exacerbations, requiring systemic corticosteroids, and progressive disease
-
Virtual reality anatomy trainer turns teaching endobronchial ultrasound inside-out. Chest (IF 9.5) Pub Date : 2024-12-09 Melissa L New,Tristan J Huie,Dru Claar,Timothy Amass,Ryan A Peterson,Max McGrath,Nicholas Jacobson,Anna Neumeier,Darlene Nelson
BACKGROUND Traditional approaches for learning anatomy for curvilinear endobronchial ultrasound (EBUS) require learners to mentally visualize structures relative to the position of the bronchoscope. Virtual reality (VR) can demonstrate anatomy from the perspective of bronchoscopic tools. RESEARCH QUESTION Does the use of a VR anatomy trainer for teaching EBUS-associated anatomy improve procedural performance
-
Leveraging Patient Advocacy and Faith-Based Partnerships to Educate, Activate, and Prepare Black Communities to be Screened for Lung Cancer. Chest (IF 9.5) Pub Date : 2024-12-05 Sydney J Lloyd,Kathy A Levy,Alana S Boyd,Joelle T Fathi
Lung cancer is the second most common and the deadliest cancer for men and women in the U.S. Historical and current-day injustices, implicit and explicit bias, stigma, social determinants, and disparities contribute to inequitable lung cancer-related health outcomes for Black and African Americans comparatively. Despite being a preventive health recommendation for over a decade, the percentage of eligible
-
The emerging role of alarmin-targeting biologics in the treatment of patients with COPD. Chest (IF 9.5) Pub Date : 2024-12-02 Bartolome R Celli,Antonio Anzueto,Dave Singh,Nicola A Hanania,Leonardo Fabbri,Fernando J Martinez,Xavier Soler,Michel Djandji,Juby A Jacob-Nara,Paul J Rowe,Yamo Deniz,Amr Radwan
TOPIC IMPORTANCE Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous lung disease characterized by persistent airflow limitation secondary to airways and parenchymal abnormalities, and respiratory symptoms, including dyspnoea, fatigue, chronic cough, and sputum production. Cigarette smoke exposure is a major contributor to COPD although inhalation of toxic particles and other environmental
-
Stability of Fractional Exhaled Nitric Oxide and its Relationship with Exacerbation in Patients Aged 6 Years or Older with Uncontrolled, Moderate-to-Severe Asthma. Chest (IF 9.5) Pub Date : 2024-12-02 William W Busse,Ian D Pavord,Michael E Wechsler,Ignacio J Davila,Arman Altincatal,Lucia de Prado Gomez,Xavier Soler,Harry Sacks,Juby A Jacob-Nara,Yamo Deniz,Paul J Rowe
-
Non- Tuberculous mycobacterial infection and pulmonary disease In Northern Israel: a focus on M. simiae. Chest (IF 9.5) Pub Date : 2024-12-02 Razi Even-Dar,Idit Raz,Maya Brodsky,Nili Stein,Yochai Adir,Walid Saliba,Shifra Ken-Dror,Ronza Najjar- Debbiny,Raya Cohen,Michal Shteinberg
BACKGROUND The prevalence of non-Tuberculous Mycobacteria pulmonary disease (NTM-pd) is rising globally. Previously, we described a high prevalence of M. simiae isolation in Israel. RESEARCH QUESTIONS What is the prevalence of NTM-pd and M. simiae-pd in Northern Israel? Which factors are associated with mortality among people with NTM? STUDY DESIGN AND METHODS We retrospectively recorded all samples
-
Further Insights and Considerations for the Study on the Impact of Epicardial Adipose Tissue on Right Cardiac Function and Prognosis in Pulmonary Arterial Hypertension. Chest (IF 9.5) Pub Date : 2024-12-01 Xiaozhen Zhao,Xiaohua Tan,Jianghong Deng,Caifeng Li
-
The Social Context and Health Care Access. Chest (IF 9.5) Pub Date : 2024-12-01 Kenneth M Nugent,Joanna L Harkey
-
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Should Be Cautiously Performed on Mediastinal Bronchogenic Cysts. Chest (IF 9.5) Pub Date : 2024-12-01 Xiao Qiong Tan,Xun Shen
-
Has the Use of Minocycline Decreased Delirium Incidence? Chest (IF 9.5) Pub Date : 2024-12-01 Wei-Hsin Hung,I Liu,James Cheng-Chung Wei
-
Further Discussion Regarding the Increased Risk of Pertussis in Populations With Asthma or COPD. Chest (IF 9.5) Pub Date : 2024-12-01 Zhou Jin
-
An 80-Year-Old Man With Intractable Cough. Chest (IF 9.5) Pub Date : 2024-12-01 Ganjam Yasaswini,Dipti Gothi,Anshul Jain,Pranzal Garg,Anu Singhal,Sanket Joshi,Ansha Sinha
An 80-year-old man with no history of substance addiction presented with complaints of cough and breathlessness for 4 months. His cough was nonproductive, waxing and waning in nature with high symptom load during daytime, but not associated with chest pain or wheezing. He gives no history of nasal or sinus symptoms, aspiration, or reflux symptoms. Breathlessness was nonparoxysmal, independent of cough
-
Improving Methodologic Approaches in COPD and Air Pollution Research. Chest (IF 9.5) Pub Date : 2024-12-01 Yating Zhou,Fei Xue
-
A 68-Year-Old Woman With a Rapidly Reaccumulating Pleural Effusion. Chest (IF 9.5) Pub Date : 2024-12-01 Michael Torres Lizardi,Gaurav Ajmani,Ajay Wagh
A 68-year-old woman presented with worsening dyspnea. She had presented to her local community hospital 10 days earlier with similar symptoms. She was diagnosed with a right-sided pleural effusion, which was attributed to pneumonia and treated with antibiotics. She underwent two thoracenteses within a week, with relief of dyspnea after each procedure. Two days after hospital discharge, she developed
-
The Great Disappearing Act: A Case of a Vanishing Right Ventricle Mass Revealed by Transesophageal Echocardiogram in Peripartum Cardiac Arrest. Chest (IF 9.5) Pub Date : 2024-12-01 Francesca C Duncan,Nakia M Hunter,William Graham Carlos,Olusayo Oshogwemoh,Edwin J Jackson
-
Zanubrutinib-Associated Recurrent Spontaneous Hemorrhagic Pleural Effusion in Chronic Lymphocytic Leukemia: Case Report. Chest (IF 9.5) Pub Date : 2024-12-01 Abdullah Javed,Dawood Javed,Muhammad Farooq Asghar
Zanubrutinib is an orally administered second-generation covalent inhibitor of Bruton tyrosine kinase that was recently approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia and small lymphocytic leukemia. It has been associated with significant major and minor bleeding events, including intracranial and GI hemorrhage and hematuria, with or without concurrent
-
A 36-Year-Old Patient With Crohn Disease and Bilateral Pleural Effusions. Chest (IF 9.5) Pub Date : 2024-12-01 Samantha M Quon,Jared E Rosen,Brett Z Schaeffer,Hanine Inaty
A 36-year-old man with severe Crohn disease complicated by urethral strictures and enterocutaneous and enterovesicular fistulas presented for several weeks of poor appetite, weight loss, failure to thrive, and newly worsening altered mentation. Further history revealed he chronically did not urinate through his urethra, but rather "leaked" through multiple enterocutaneous fistulas in his abdomen and
-
Keep Gimmicks of Toy E-Cigarettes Away and Juveniles on Track Towards the Tobacco Endgame. Chest (IF 9.5) Pub Date : 2024-12-01 Nobel Chenggong Zong,Yuhan Zhang,Hua Cai
-
-
Alpha-1 Antitrypsin Deficiency: Navigating Challenges Through Collaborative Innovation. Chest (IF 9.5) Pub Date : 2024-12-01 Gina Smith,Kanwaljit Singh
-
Addressing Inequality in Interstitial Lung Disease Care in the United States-Mexico Border Region and Beyond. Chest (IF 9.5) Pub Date : 2024-12-01 Alison M DeDent,Timothy M Dempsey
-
"Suction vs Gravity: A Distinction Without a Difference?": Insights From a Multicenter Randomized Trial on Speed and Safety of Two Pleural Fluid Draining Methods. Chest (IF 9.5) Pub Date : 2024-12-01 Prince Ntiamoah,Septimiu Murgu
-
COUNTERPOINT: Is It Ethically Justifiable to Withdraw Extracorporeal Membrane Oxygenation Against the Wishes of a Patient With Decision-Making Capacity When Cure Is Not Possible? No. Chest (IF 9.5) Pub Date : 2024-12-01 Andrew M Childress
-
A Cure or a Cause: Multiple Listing and Lung Transplantation Disparities. Chest (IF 9.5) Pub Date : 2024-12-01 Olawale Amubieya,S Sam Weigt
-
Palliative Care for Advanced Pulmonary Diseases: A Call to Action. Chest (IF 9.5) Pub Date : 2024-12-01 Anne Song,Joanna L Hart
-
POINT: Is It Ethically Justifiable to Withdraw Extracorporeal Membrane Oxygenation Against the Wishes of a Patient With Decision-Making Capacity When Cure Is Not Possible? Yes. Chest (IF 9.5) Pub Date : 2024-12-01 Alexander A Kon
-
"Breathing Through the Years": A Call for Combating Breathlessness, Frailty, and Sarcopenia in Older Adults. Chest (IF 9.5) Pub Date : 2024-12-01 Tejaswini Kulkarni,Merry Lynn McDonald
-
Dexmedetomidine for Decatecholaminization in Septic Shock: Insights and Challenges? Chest (IF 9.5) Pub Date : 2024-12-01 Daisuke Hasegawa,Ryota Sato
-
Optimizing RBC Transfusion Management in Patients on Venovenous Extracorporeal Membrane Oxygenation. Chest (IF 9.5) Pub Date : 2024-12-01 Nareg H Roubinian,Richard Ha
-
Under Press(or): Press on With Early Administration of Vasopressors. Chest (IF 9.5) Pub Date : 2024-12-01 Robert MacLaren
-
COPD Exacerbations and Future Risk of Serious Cardiovascular Events. Chest (IF 9.5) Pub Date : 2024-12-01 Shawn D Aaron
-
The Minnesota Critical Care Working Group 1: Monitoring and coordinating statewide critical care surge response in the COVID-19 pandemic, March 2020 through July 1, 2021. Chest (IF 9.5) Pub Date : 2024-11-30 Jeffrey R Dichter,Daniel Brown,Clara Zamorano,Joshua Cohen,Elizabeth A Miller,David E Niccum,Michele LeClaire,Christina Bastin De Jong,Deanna Diebold,Jacob Lyons,Ronald Reilkoff,Heidi L Erickson,Joseph Martinelli,Jennifer A Fischer,Kyle Mairose,Jason Kallestad,Christine Chell,Adam Shadiow,Shawn Stoen,John L Hick,Cheryl Petersen-Kroeber,Judy Seaberg,Erin McLachlan,Alexandra T Waterman,Walter Y James
BACKGROUND In response to the COVID-19 pandemic and as part of the statewide healthcare coalition response the Minnesota Critical Care Working Group (CCWG), composed of Interprofessional leaders from the state's nine largest health systems was established and entrusted to plan and coordinate critical care support for Minnesota from March 2020 through July1, 2021. RESEARCH QUESTION Can a statewide Critical
-
Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. Chest (IF 9.5) Pub Date : 2024-11-30 R James White,Karim El-Kersh,Stephan Rosenkranz,Veronica Franco,Carmine Dario Vizza,Roberto Badagliacca,Joanna Pepke-Zaba,Jean Elwing,Rahul G Argula,Shelley Shapiro,Hyoshin Kim,Scott Seaman,Eric Shen,Manisit Das,Meredith Broderick,Vallerie McLaughlin
BACKGROUND An increasing number of patients with pulmonary arterial hypertension (PAH) have cardiovascular comorbidities. However, the effects of comorbidities on responses to PAH treatment are not well understood. RESEARCH QUESTION Do cardiovascular comorbidities in patients with PAH influence the efficacy and tolerability of inhaled or oral treprostinil? STUDY DESIGN AND METHODS All patients from
-
Improving A Rapid Response System at a Teaching Hospital: Lessons Learned From Implementation of a Novel Performance Self-Evaluation Tool. Chest (IF 9.5) Pub Date : 2024-11-29 Henrik Ghantarchyan,Alexander T Phan,Aldin Malkoc,Jasmine Toor,Janet Gukasyan,Aftab Qadir,Sarkis Arabian
Rapid assessment and treatment (RAT) calls, facilitated by Rapid Response Teams (RRTs), have become vital to the care of hospitalized patients deteriorating outside of the intensive care unit in many institutions worldwide. A significant body of data has recognized the efficacy of rapid response systems (RRSs) in improving patient care; however, there is no standardized protocol that all RRSs practice
-
ANALYSIS OF THE EFFECT OF AGE DIFFERENCES ON ATRIAL FIBRILLATION RECURRENCE POST INDEX ABLATION Chest (IF 9.5) Pub Date : 2024-11-29 Juzer Ali, Asgar Amal, Benchakroun Ashvin, Zachariah Mariel, Duchow Arie, Szeinfeld Leonard, Efuet-Ateh Harrison, Koss Kevin, Bliden Udaya, Tantry Paul Gurbel, Robert Chait
-
Treatment of Acute Circulatory Failure Based on CO2-O2-Derived Indices: the Lactel randomized multicentre study. Chest (IF 9.5) Pub Date : 2024-11-28 Pierre-Grégoire Guinot,Corentin Evezard,Maxime Nguyen,Pili-Floury Sebastien,Vivien Berthoud,Guillaume Besch,Belaid Bouhemad
BACKGROUND Acute circulatory failure is critical in ICU patients. CO2-O2-derived indices including the central venous-to-arterial CO2 difference (P(v-a)CO2 gap) and the P(v-a)CO2 gap/Ca-vO2 ratio are markers for global metabolic demand and tissue hypoxia. RESEARCH QUESTION Does a resuscitation strategy using CO2-O2-derived indices improve tissular hypoperfusion compared to standard care? STUDY DESIGN
-
How I Do It: Nurse Practitioners and Physician Assistants: Building a Team and Optimizing Practice in the Medical ICU. Chest (IF 9.5) Pub Date : 2024-11-27 Carolyn Dickens,Amber Beserra,Joe Keller,Susan Corbridge,Melissa Carlucci
The integration of Nurse Practitioners (NPs) and Physician Assistants (PAs) in the Medical Intensive Care Unit (MICU) is becoming increasingly vital due to the rising number of critically ill patients and the shortage of board-certified intensivists. Successful recruitment and utilization of NPs and PAs into the MICU setting require a unique understanding of potential variations of the scope of practice
-
Epicardial Adipose Tissue Is an Independent Risk Factor for Mortality in Pulmonary Arterial Hypertension. Chest (IF 9.5) Pub Date : 2024-11-27 Breanne E McCarthy,Rui Feng,Drew A Torigian,Yubing Tong,Jason S Fritz,Jasleen K Minhas,Jeremy A Mazurek,K Akaya Smith,Harold I Palevsky,Steven C Pugliese,Natalie Z Homer,Margaret R MacLean,Jayaram K Udupa,Nadine Al-Naamani
BACKGROUND Increased epicardial adipose tissue (EAT) has adverse effects in cardiovascular diseases, independent of body mass index (BMI). Estrogen levels may impact EAT accumulation. Little is known about the predictors and potential impact of EAT in PAH. RESEARCH QUESTION Is EAT associated with estrogen levels, disease severity, and mortality in PAH? STUDY DESIGN AND METHODS We conducted a retrospective
-
The Minnesota Critical Care Working Group 2: Crisis conditions during the COVID-19 Pandemic, July 2021 through March 2022. Chest (IF 9.5) Pub Date : 2024-11-27 Sarah M Kesler,Christina Bastin De Jong,Christine Chell,Debra DeBruin,Heidi L Erickson,Kimberly A Goodman,Walter James,Jason Kallestad,Tom Klemond,Erin McLachlan,Cheryl Petersen-Kroeber,James Risser,Erin S DeMartino,Alexandra T Waterman,Susan M Wolf,Joel Wu,Clara Zamorano,Karyn Baum,Daniel Brown,Joshua Cohen,Deanna Diebold,Jennifer A Fischer,Kay Greenlee,John Hick,Paul Kettler,Michele LeClaire,Jacob
BACKGROUND At the request of the Statewide Healthcare Coordination Center, the Minnesota Critical Care Working Group (CCWG) and ethics subgroup (EWG), composed of interprofessional leaders from Minnesota's nine largest health systems were asked to plan and coordinate critical care operations during the COVID-19 pandemic, including the 2021 Fall surge. RESEARCH QUESTION Can a statewide Working Group
-
Plasma Protein Biomarkers of Spirometry Measures of Impaired Lung Function Chest (IF 9.5) Pub Date : 2024-11-22 Mohit Aggarwal, Shih-Jen Hwang, Dong Heon Lee, Tianxiao Huan, Jenna N. McNeill, Paul Courchesne, Roby Joehanes, Jennifer E. Ho, Josée Dupuis, Åsa K. Hedman, George O’Connor, Daniel Levy MD
Impaired pulmonary function carries significant risks for lung, cardiovascular, and metabolic disorders.
-
Chronic obstructive pulmonary disease-associated expiratory central airway collapse: current concepts and new perspectives. Chest (IF 9.5) Pub Date : 2024-11-21 Pengcheng Zhou,Wei Yu,Wensheng Zhang,Jianli Ma,Qianming Xia,Chengshi He
TOPIC IMPORTANCE Chronic obstructive pulmonary disease (COPD)-associated expiratory central airway collapse (ECAC) is a frequently overlooked benign airway obstructive disease, with complex causes and unclear pathological and physiological mechanisms. Although interventions such as noninvasive positive pressure ventilation, airway stenting, and tracheobronchoplasty have shown definite efficacy in the
-
Evolution of DLCO in LAM: Historical Perspectives and the Role of Advanced Imaging. Chest (IF 9.5) Pub Date : 2024-11-21 Bennett E Yang,Jason M Elinoff,Adrienne E Campbell-Washburn,Han Wen,Joel Moss
Lymphangioleiomyomatosis (LAM) is a rare cystic lung disease affecting women and is characterized by the proliferation of abnormal smooth muscle-like cells within the lungs, kidneys, and lymphatic system. Forced expiratory volume in 1 second (FEV1) and diffusing capacity of the lungs for carbon monoxide (DLCO) are two commonly used markers for evaluating the status of LAM, although the disease may
-
Keeping up with technological innovation: the moral imperative for pragmatic clinical trials in interventional pulmonology. Chest (IF 9.5) Pub Date : 2024-11-20 Fabien Maldonado,Rafael Paez,Robert J Lentz,Ankush Ratwani,Jonathan D Casey
The advances in minimally invasive lung cancer diagnostics of the last decade have transformed patient care but have also raised important concerns about the regulatory processes used to approve new devices and the best way to generate data to support their use. Disruptive technologies, such as robotic bronchoscopy, have been widely adopted by interventional pulmonologists in the absence of robust
-
Pulmonary Hypertension Associated With Trastuzumab-Emtansine: An Analysis of French PH Registry and WHO Pharmacovigilance Database Chest (IF 9.5) Pub Date : 2024-11-19 Camille Poisson MD, Alex Hlavaty PharmD, Nicolas Favrolt MD, Marie-Camille Chaumais PharmD PhD, Julien Grynblat MD, Etienne-Marie Jutant MD PhD, Benoît Lechartier MD, Arnaud Maurac MD, Pierre Mouillot MD, Sylvain Palat MD, Laurie Rambach MD, Fabrice Antigny PhD, Vincent Cottin MD PhD, Guillaume Beltramo MD, Marc Humbert, Charles Khouri MD PhD, Philippe Bonniaud MD PhD, David Montani MD PhD
Trastuzumab emtansine has been recently suspected to be associated with the development of pulmonary arterial hypertension (PAH).
-
Lung Nodules and Masses in non-HIV Immunocompromised Patients: A Clinical-Imaging Algorithmic Approach. Chest (IF 9.5) Pub Date : 2024-11-19 T Franquet,S Raoof,Ks Lee,J Han,A Gimenez,Jm Brenes,J Asmar,P Domingo
TOPIC IMPORTANCE The incidence of pulmonary nodules and masses in non-HIV immunocompromised patients has significantly increased due to advancements in hematopoietic stem cell transplantation (HSCT), solid organ transplantation (SOT), and the widespread use of chemotherapy and immunosuppressive therapies. Differentiating between infectious and non-infectious causes is critical for appropriate diagnosis
-
Dietary pattern, sputum DNA methylation, and lung health: an epidemiological study in people who ever smoked. Chest (IF 9.5) Pub Date : 2024-11-19 Yue Feng,Huining Kang,Akshay Sood,Dolores D Guest,Teresa T Fung,Cassie L Rowe,Maria A Picchi,Vernon Shane Pankratz,Steven A Belinsky,Shuguang Leng
BACKGROUND We previously identified a panel of sputum DNA methylation that predicts lung ageing and risk for lung cancer. RESEARCH QUESTION Can the sputum methylation panel be used as a readout to derive a dietary pattern beneficial for lung health? Is this dietary pattern associated with various subjective and objective lung health phenotypes? Does this relationship vary among people who currently
-
Associations of socioeconomic status and phenotypic frailty with incident chronic obstructive pulmonary disease: findings from UK Biobank participants. Chest (IF 9.5) Pub Date : 2024-11-15 Zhaolong Feng,Guoxian Li,Qida He,Na Sun,Tongxing Li,Qiang Han,Hanqing Zhao,Ze Ma,Mengtong Sun,Boyan Liu,Yu Wang,Zexin Lou,Siqian Ma,Yujie Shi,Jianing Li,Ziqing Sun,Miao Jiang,Yueping Shen
BACKGROUND The independent, mediation, interaction, and joint effects of socioeconomic status (SES) and phenotypic frailty on the incidence of chronic obstructive pulmonary disease (COPD) are unclear. RESEARCH QUESTION Do SES and frailty increase the risk of COPD independently or jointly ? Is there an interaction between the two factors in incident COPD? Does frailty play a mediating role between SES
-
Clinical Accuracy and Risk of Harm in Asthma-Related Content on TikTok Chest (IF 9.5) Pub Date : 2024-11-09 Emma McNally, John Murray, Brian D. Kent
-
Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease Chest (IF 9.5) Pub Date : 2024-11-09 Stephen M. Humphries, Ayodeji Adegunsoye, M. Kristen Demoruelle, Michelle Li Wei Kam, Isabelle Amigues, Tami J. Bang, Shawn D. Teague, David A. Lynch, Jonathan H. Chung, Mary E. Strek, Jeffrey J. Swigris, Joshua J. Solomon
Quantitative CT imaging may be a useful predictor of outcome in rheumatoid arthritis-related interstitial lung disease (RA-ILD).
-
Results of the SHARP Study: A Randomized, Placebo-Controlled, Double-Blind, Repeated-Measures, Crossover, Phase IV Clinical Trial of the Effect of the Wake-Promoting Agent Solriamfetol on Cognitive Function in OSA With Excessive Daytime Sleepiness and Cognitive Impairment Chest (IF 9.5) Pub Date : 2024-11-09 Hans P.A. Van Dongen PhD, Eileen B. Leary PhD RPSGT, Christopher Drake PhD, Richard Bogan MD FCCP, Judith Jaeger PhD MPA, Russell Rosenberg PhD, Caroline Streicher BA, Herriot Tabuteau MD
OSA causes episodes of fragmented sleep and intermittent hypoxia and leads to excessive daytime sleepiness (EDS). Deficits in cognitive function are a troublesome symptom in patients with OSA and EDS.
-
Effects of β-Blockers on the Outcomes in Patients With Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: A Multicenter Prospective Cohort Study (BNP-PL) Chest (IF 9.5) Pub Date : 2024-11-09 Marcin Waligóra, Marcin Kurzyna, Tatiana Mularek-Kubzdela, Ilona Skoczylas, Łukasz Chrzanowski, Piotr Błaszczak, Miłosz Jaguszewski, Beata Kuśmierczyk, Katarzyna Ptaszyńska, Grzegorz Grześk, Katarzyna Mizia-Stec, Ewa Malinowska, Małgorzata Peregud-Pogorzelska, Ewa Lewicka, Michał Tomaszewski, Wojciech Jacheć, Michał Florczyk, Ewa Mroczek, Zbigniew Gąsior, Agnieszka Pawlak, Katarzyna Betkier-Lipińska
Current guidelines do not recommend β-blockers in pulmonary arterial hypertension (PAH) unless indicated by comorbidities. However, the evidence regarding the role of β-blockers in PAH is contradictory.
-
Comparison of Clinically Meaningful Improvements After Center-Based and Home-Based Telerehabilitation in People With COPD Chest (IF 9.5) Pub Date : 2024-11-09 Narelle S. Cox PhD, Christine McDonald PhD, Angela T. Burge PhD, Catherine J. Hill PhD, Janet Bondarenko MSc, Anne E. Holland PhD
Response to pulmonary rehabilitation is not equal for all participants and may vary across health outcomes for any one individual. Alternative methods of pulmonary rehabilitation delivery, for example, telerehabilitation, may improve program access, but also could affect response to rehabilitation.
-
Sarcoidosis Treatment Patterns in the United States: 2016-2022 Chest (IF 9.5) Pub Date : 2024-11-09 Ruchika Sangani MD, Nicholas A. Bosch MD, Praveen Govender MB BCh, Brittany Scarpato MD, Allan J. Walkey MD, Julia Newman MD, Anica C. Law MD, Kari R. Gillmeyer MD, Divya A. Shankar MD
There are limited US Federal Drug Administration-approved medications and real-world data on sarcoidosis treatment in the United States. Concordance of practice patterns with guideline recommendations have not been well characterized.
-
Lessons Learned: Risk Factors and Clinical Impact of Severe Pneumothorax After Endoscopic Lung Volume Reduction With Endobronchial Valves Chest (IF 9.5) Pub Date : 2024-11-08 Judith Maria Brock, Susanne Annemarie Dittrich, Florian Eichhorn, Kai Schlamp, Konstantina Kontogianni, Felix J.F. Herth
Pneumothorax is a major complication after endoscopic lung volume reduction with valves, with a prevalence of up to 34%. Although some patients benefit from valve implantation despite pneumothorax, others are significantly impaired after lung collapse.
-
The Dawn of Precision Medicine in Fibrotic Interstitial Lung Disease Chest (IF 9.5) Pub Date : 2024-11-08 Theodoros Karampitsakos, Bochra Tourki, Jose D. Herazo-Maya MD
Interstitial lung diseases (ILDs) represent a broad group of heterogeneous parenchymal lung diseases. Some ILDs progress, causing architectural distortion and pulmonary fibrosis, and thus are called fibrotic ILDs. Recent studies have shown a beneficial effect of antifibrotic therapy in fibrotic ILDs other than idiopathic pulmonary fibrosis (IPF) that manifest progressive pulmonary fibrosis (PPF). However